Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronate for 12 versus 36 months in multiple myeloma
ISRCTN23172547Phase 3Completed
- Sponsor
- HOVON
- Start
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronate in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoint: Time to first skeletal-related event from randomization. Started Apr 2004; status: completed.
02
Drugs
zoledronate
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN23172547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN23172547.